Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2013 07:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference

TORONTO, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
November 27, 2013 16:30 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces At-The-Market Offering of Common Shares

TORONTO, Nov. 27, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
November 18, 2013 16:34 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R)

– FDA Issues Final Approval of 15 mg, With 180 Days of Exclusivity, and 30 mg; and – Tentative Approvals for the Company's 5, 10, 20 and 40 mg Strengths TORONTO, Nov. 18, 2013...
October 01, 2013 17:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Third Quarter 2013 Results

TORONTO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
July 31, 2013 17:25 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Closes Public Offering for US$3.1 Million

TORONTO, July 31, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
July 26, 2013 09:29 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Pricing of Public Offering of Common Shares and Warrants

TORONTO, July 26, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
July 26, 2013 02:06 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants

TORONTO, July 26, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
July 15, 2013 07:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Updates Developments on Its Rexista(TM) Oxycodone Technology

TORONTO, July 15, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
July 02, 2013 18:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Second Quarter 2013 Results

TORONTO, July 2, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and...
April 24, 2013 17:00 ET | Source: Intellipharmaceutics International Inc.

Intellipharmaceutics Announces Webcast of Presentation at the 12th Annual Needham Healthcare Conference

TORONTO, April 24, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...